Get the Stockscreener App
22.10
3.56%
0.76
After Hours:
22.80
0.70
+3.17%
Roivant Sciences Ltd stock is traded at $22.10, with a volume of 12.37M.
It is up +3.56% in the last 24 hours and up +3.66% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$21.34
Open:
$21.77
24h Volume:
12.37M
Relative Volume:
1.51
Market Cap:
$15.37B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
3.9115
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
+5.39%
1M Performance:
+3.66%
6M Performance:
+92.68%
1Y Performance:
+86.03%
1-Day Range:
$21.39
$22.45
1-Week Range:
$20.14
$22.45
52-Week Range:
$8.73
$22.45
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
22.10 | 14.84B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
BlackBarn Capital Partners LP Sells 125,000 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences stock holds Buy rating at Guggenheim after timeline updates By Investing.com - Investing.com South Africa
Massive Stock Acquisition: Roivant Sciences Bets Big on Immunovant - TipRanks
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares - MarketBeat
Roivant Sciences Boosts Investor Confidence With Advancements and Financing Moves - StocksToTrade
HC Wainwright & Co. Maintains Roivant Sciences (ROIV) Buy Recommendation - Nasdaq
Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m By Investing.com - Investing.com Canada
Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m - Investing.com
Roivant Sciences Sees Strategic Consolidation with Key Drug Advancements - timothysykes.com
Roivant Sciences Eyes Strategic Growth: Key Analyst Updates and Development Plans - timothysykes.com
Roivant Sciences stock holds Buy rating at Guggenheim after timeline updates - Investing.com Australia
Roivant Sciences (ROIV) president Venker sells $4.17 million in shares By Investing.com - Investing.com Australia
Roivant Sciences (ROIV) president Venker sells $4.17 million in shares - Investing.com
Roivant Updates Investors On Mosliciguat Development Plans - Citeline News & Insights
Why Is Roivant Sciences Stock Gaining Thursday?Roivant Sciences (NASDAQ:ROIV) - Benzinga
Roivant Sciences (NASDAQ:ROIV) Reaches New 52-Week HighHere's Why - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Reaches New 1-Year HighHere's What Happened - MarketBeat
Price-Driven Insight from (ROIV) for Rule-Based Strategy - news.stocktradersdaily.com
Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts - ts2.tech
HighVista Strategies LLC Sells 54,058 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant accelerates timeline for key drug programs, plans multiple launches By Investing.com - Investing.com Australia
Roivant Sciences Ltd Highlights Pipeline Progress at 2025 Investor Day - TradingView — Track All Markets
Roivant highlights continued pipeline progress and outlook for company's next phase of growth at 2025 Investor Day - marketscreener.com
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day - marketscreener.com
Roivant (Nasdaq: ROIV) outlines 3+ launches as $550M Immunovant deal extends runway - Stock Titan
Marshall Wace LLP Acquires 683,327 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Immunovant Announces Pricing of $550 Million Common Stock Financing - The Manila Times
Immunovant (Nasdaq: IMVT) raises $550M to support potential IMVT-1402 Graves’ launch - Stock Titan
Psivant Therapeutics, Inc. announced that it has received $47.5 million in funding from YK Bioventures, Samsara BioCapital LLC, Roivant Sciences Ltd., LSV Capital Management, LLC, Eurofarma Laboratórios S.A. and other investos - marketscreener.com
A former Roivant spinout bets on AI-designed drugs for immune conditions - Yahoo Finance
iSAM Funds UK Ltd Grows Stock Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences stock hits all-time high at $21.36 By Investing.com - Investing.com Canada
Roivant Sciences stock hits all-time high at $21.36 - Investing.com
Roivant Sciences Ltd. $ROIV is SB Investment Advisers UK Ltd.'s 3rd Largest Position - MarketBeat
88,495 Shares in Roivant Sciences Ltd. $ROIV Acquired by Franklin Resources Inc. - MarketBeat
Cash per share of Roivant Sciences Ltd. – MUN:87S - TradingView
Affinity Asset Advisors LLC Purchases 250,000 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Earnings Beat: Why Roivant Sciences Ltd stock could rally in 2025Quarterly Portfolio Report & High Return Trade Guides - moha.gov.vn
Roivant Sciences Ltd. $ROIV Position Increased by Two Seas Capital LP - MarketBeat
Roivant Sciences Ltd. $ROIV Shares Sold by Pertento Partners LLP - MarketBeat
Is Roivant Sciences Ltd. stock safe for conservative investors2025 Winners & Losers & Daily Profit Focused Screening - Newser
Is Roivant Sciences Ltd. (87S) stock safe for risk averse investorsJuly 2025 Fed Impact & High Yield Stock Recommendations - Newser
Why Roivant Sciences Ltd. stock could rally in 2025Dividend Hike & Weekly Breakout Watchlists - Newser
How Roivant Sciences Ltd. (87S) stock compares with market leadersJuly 2025 Trends & Community Verified Trade Signals - Newser
Is Roivant Sciences Ltd. (87S) stock undervalued by metricsWeekly Trend Recap & High Conviction Buy Zone Alerts - Newser
Will Roivant Sciences Ltd. stock recover faster than peers2025 Market Overview & Capital Efficiency Focused Strategies - Newser
How Roivant Sciences Ltd. (87S) stock trades after rate cutsM&A Rumor & High Win Rate Trade Tips - Newser
Roivant Sciences Ltd. (ROIV) Stock Forecasts - Yahoo Finance
Why analysts recommend Roivant Sciences Ltd. (87S) stockJuly 2025 Sector Moves & Consistent Profit Trade Alerts - Newser
Is Roivant Sciences Ltd. (87S) stock prepared for digital transitionWeekly Trend Summary & Fast Entry High Yield Stock Tips - Newser
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):